阿替普酶与重组链激酶用于急诊治疗ST段抬高型心肌梗死的疗效对比研究

Comparative analysis of the efficacy of ateplase and recombinant streptokinase in the emergency treatment of ST segment elevation myocardial infarction

目的对比分析阿替普酶与重组链激酶用于急诊治疗ST段抬高型心肌梗死的疗效。方法选取2018年12月至2020年1月该院收治的ST段抬高型心肌梗死患者90例,根据不同临床治疗药物分为研究组和参照组,每组45例。研究组采用阿替普酶进行治疗,参照组采用重组链激酶进行治疗。分析两组患者治疗后血管再通情况和发生不良事件的概率。结果与参照组比较,研究组患者血管再通情况更佳,治疗后期发生不良事件的概率更低,差异均有统计学意义(P<0.05)。结论阿替普酶治疗ST段抬高型心肌梗死的效果更佳。

Objective To compare the efficacy of ateplase and recombinant streptokinase in the treatment of ST segment elevation myocardial infarction.Methods A total of 90 patients with ST segment elevation myocardial infarction were divided into study group(n=45)and reference group(n=45).The study group was treated with alteplase and the reference group was treated with recombinant streptokinase.The vascular recanalization and the probability of adverse events were analyzed.Results The vascular recanalization was better in the study group,and the incidence of adverse events in the later period of treatment was lower than that in the reference group(P<0.05).Conclusion The effect of ateplase is better in the treatment of ST segment elevation myocardial infarction.